Novel peptide ligands of leukocyte integrins
CA 2441210 A1 · Owner: Gahmberg, Carl G. · Inventors: Koivunen, Erkki; Gahmberg, Carl G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel peptides which are useful as antagonists of the .beta.2 integrins, to pharmaceutical compositions comprising these peptides, to the use of the novel peptides for the manufacture of pharmaceutical compositions for the treatment of inflammatory diseases and human leukemias and for inhibiting leukocyte cell adhesion and migration in general, to a method for therapeutic or prophylactic treatment of inflammatory diseases and human leukemias and to the use of the novel peptides as .beta.2 integrin antagonists for biochemical isolation and purification procedures in vitro.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 11, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 11, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 11, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.